Becton, Dickinson and Company (BDX) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
BDX Revenue Growth
Revenue Breakdown (FY 2025)
BDX's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
BDX Revenue Analysis (2014–2025)
As of May 8, 2026, Becton, Dickinson and Company (BDX) generated trailing twelve-month (TTM) revenue of $21.36 billion, reflecting significant decline in growth of -10.6% year-over-year. The most recent quarter (Q2 2026) recorded $4.71 billion in revenue, down 10.2% sequentially.
Looking at the longer-term picture, BDX's 5-year compound annual growth rate (CAGR) stands at +6.3%, indicating steady revenue expansion. The company achieved its highest annual revenue of $21.84 billion in 2025, representing a new all-time high.
Revenue diversification analysis shows BDX's business is primarily driven by Medical (52%), Interventional (24%), and Life Sciences (24%). With over half of revenue concentrated in Medical, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including BAX (+5.1% YoY), BSX (+19.9% YoY), and MDT (+6.9% YoY), BDX has underperformed the peer group in terms of revenue growth. Compare BDX vs BAX →
BDX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| BDXCurrent | $21.4B | -10.6% | +6.3% | 11.8% | |
 BAX | $11.2B | +5.1% | -0.7% | -2.7% | |
 BSX | $20.1B | +19.9% | +15.2% | 19.8% | |
 MDT | $33.5B | +6.9% | +3.0% | 17.8% | |
 SYK | $25.1B | +11.2% | +11.8% | 19.5% | |
 ZBH | $8.2B | +9.2% | +6.1% | 16.5% |
BDX Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $21.84B | +8.2% | $9.92B | 45.4% | $2.58B | 11.8% |
| 2024 | $20.18B | +4.2% | $9.13B | 45.2% | $2.40B | 11.9% |
| 2023 | $19.37B | +2.7% | $8.17B | 42.2% | $2.11B | 10.9% |
| 2022 | $18.87B | -1.4% | $8.48B | 44.9% | $2.28B | 12.1% |
| 2021 | $19.13B | +19.0% | $8.63B | 45.1% | $2.25B | 11.8% |
| 2020 | $16.07B | -7.0% | $6.80B | 42.3% | $912.0M | 5.7% |
| 2019 | $17.29B | +8.2% | $8.29B | 47.9% | $1.76B | 10.2% |
| 2018 | $15.98B | +32.2% | $7.27B | 45.5% | $1.51B | 9.4% |
| 2017 | $12.09B | -3.1% | $5.96B | 49.3% | $1.52B | 12.6% |
| 2016 | $12.48B | +21.4% | $5.99B | 48.0% | $1.43B | 11.5% |
Full BDX Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See BDX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BDX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BDX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBDX — Frequently Asked Questions
Quick answers to the most common questions about buying BDX stock.
Is BDX's revenue growth accelerating or slowing?
BDX revenue declined -10.6% year-over-year, contrasting with the 5-year CAGR of +6.3%. TTM revenue fell to $21.4B. This reverses the prior growth trend.
What is BDX's long-term revenue growth rate?
Becton, Dickinson and Company's 5-year revenue CAGR of +6.3% reflects the variable expansion pattern. Current YoY growth of -10.6% is below this long-term average.
How is BDX's revenue distributed by segment?
BDX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.